Insilico Medicine, Biopharmaceuticals Strike: AI Drug Deal Heads Toward $2.5B
Insilico Medicine and SK Biopharmaceuticals unveiled a milestone collaboration worth up to $2.5 billion to develop ne...
Curious about accumulating points? Learn which card is best for accumulating points and elevate your rewards strategy effectively.
24,231 articlesInsilico Medicine and SK Biopharmaceuticals unveiled a milestone collaboration worth up to $2.5 billion to develop ne...
A Portland, Oregon court filing shows Compass has settled the Murch TCPA lawsuit. The terms are confidential, and a n...
Seltz announced a $12.5 million seed round to redefine how AI agents surface information. The funding underscores a g...
Midweek market news can move fast. This Wednesday reads guide curates clear, actionable investing ideas—from AI hype ...
Three Buy-rated names are drawing fresh attention in June as Wall Street echoes a defensive, cash-flow bias. AutoZone...
A leading analyst has reiterated a $250 SpaceX target, arguing that SpaceX's physical AI capabilities could reshape r...
In a volatile year, personal-finance experts advocate patience over rash bets. The uncertainty paradox: believe not, ...
Beijing injects 300 billion yuan into short-term funding through an overnight reverse repo, a move traders are watchi...
Investors are racing to price in the first real revenue opportunities from quantum tech as a new federal funding push...
Investors confront a tough choice: buy Nvidia for big gains or rely on NVDY's weekly income stream, which comes with ...
PTIR's double-leveraged bet on Palantir underperformed the stock by nearly half over the past year, underscoring the ...
June’s jobs data surprised markets with a modest gain of 57,000 positions. Here’s how this surprising print could sha...